



Director/PDMR Shareholding

October 1, 2020 11:00 AM EDT

Released : October 01, 2020 07:00

RNS Number : 6925A
MaxCyte, Inc.
01 October 2020

MaxCyte, Inc. ("MaxCyte" or the "Company")

Director Dealings

Maryland, USA - 1 October 2020: MaxCyte (LSE: MXCT, MXCS), the global cell-based medicines and life sciences company, announces that J. Stark Thompson, Non-Executive Chairman of the Company, has exercised options over 25,000 shares of common stock of 0.1 pence of the Company ("Common Stock") ("Exercise"). In order to fund a near term personal tax liability, the 25,000 new shares of Common Stock issued pursuant to the Exercise ("New Common Stock") have today been sold by Dr Thompson at a price of £3.55 pence per Common Stock ("Sale"). Dr Thompson has no current intention of making further sales of MaxCyte shares.

Following the Exercise and Sale, Dr Thompson's holding of Common Stock remains unchanged at a total of 110,918 Common Stock representing a total of 0.14% of the issued share capital of the Company. Dr Thompson holds a further 241,333 options over Common Stock.

Total voting rights

The New Common Stock will be allocated out of the common stock the subject of the block listing announced on 2 May 2017. The New Common Stock will rank *pari passu* with the existing shares of common stock of the Company. The total issued stock capital of the Company following the above will be 77,305,169 shares of common stock. Shareholders in the Company may use this figure as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the stock capital of the Company.

The number of unrestricted shares of Common Stock trading under the symbol 'MXCT' is 67,405,080 and the number of restricted shares of Common Stock trading under the symbol 'MXCS' is 9,900,089.

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 ("MAR").

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

1	Details of the person discharging managerial responsibilities/person closely associated	
a)	Name	J. Stark Thompson
2	Reason for the notification	

a)	Position/status	Non-Executive Chairman and PDMR	
b)	Initial notification/Amendment	Initial notification	
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	MaxCyte, Inc.	
b)	LEI	54930053YHXULRFCU991	
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted		
a)	Description of the financial instrument, type of instrument	Ordinary shares of 0.1 pence each	
b)	Identification Code	US57777K1060	
c)	Nature of the transaction	Exercise of options and Sale of Common Stock by PDMR	
d)	Price(s) and volume(s)	Price(s)	Volume(s)
		£3.55	25,000
e)	Aggregated information - Aggregated volume - Price	N/A (Single Transaction)	
f)	Date of the transaction	1.10.20	
g)	Place of the transaction	London Stock Exchange, AIM Market (XLON)	

About MaxCyte

MaxCyte is a clinical-stage global cell-based therapies and life sciences company. As the inventors of the premier cell-engineering enabling technology, the Company helps bring the promise of next-generation cell and gene-editing therapies to life. The Company's technology is currently being deployed by leading drug developers worldwide, including all of the top ten global biopharmaceutical companies. MaxCyte licences have been granted for more than 120 cell therapy programmes, with more than 90 licensed for clinical use, and the Company has now entered into eleven clinical/commercial license partnerships with leading cell therapy and gene editing developers. MaxCyte was founded in 1998, is listed on the London Stock Exchange (AIM:MXCT, MXCL) and is headquartered in Gaithersburg, Maryland, US. For more information, visit www.maxcyte.com.

For further information, please contact:

MaxCyte Inc.

+1 301 944 1660

Doug Doerfler, Chief Executive Officer

Amanda Murphy, Chief Financial Officer

Nominated Adviser and Joint Corporate Broker +44 (0)20 7886 2500

Panmure Gordon

Emma Earl

Freddy Crossley

Corporate Broking

Rupert Dearden

Joint Corporate Broker +44 (0)20 7260 1000

Numis Securities Limited

James Black

Duncan Monteith

Financial PR Adviser

+44 (0)203 709 5700

Consilium Strategic Communications

maxcyte@consilium-comms.com

Mary-Jane Elliott

Chris Welsh

Sukaina Virji

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DSHEAENEDEAEEAA